Health Condition 1: L309- Dermatitis, unspecified Health Condition 2: L309- Dermatitis, unspecified
Conditions
Interventions
Intervention1: 1.Safuf-e-Musaffi-e-Khas (oral)
2.Marham (Topical)
: 1.Safuf-e-Musaffi-e-Khas
Dosage form:powder
Dose:5gm OD
Mode of administration:oral
Composition of Safuf-e-Musaffi-e-Khas:
Amla (K
Sponsors
National Research Institute of Unani Medicine for Skin Disorders
Eligibility
Inclusion criteria
Inclusion criteria: 1.Participants of any gender between 18 to 65 years 2.Participants having the following any signs and symptoms of disease likeItching, Erythema, Visible flexural eczema, Excoriation, Hyperpigmentation, Burning sensation,Lichenification, Crusting, Dry skin 3.Chronicity of more than 6 months and less than 2 years
Exclusion criteria
Exclusion criteria: 1.Known cases of significant Pulmonary/Cardiovascular/Hepato-renal Dysfunction, Malignancy, HIV infection, AIDS, etc. 2.Any other clinical condition that in the opinion of the investigator wouldcompromise the patient’s safety or successful participation in the trial. 3.Pregnancy and Lactation 4. Known allergy, sensitivity or intolerance to the study drug or any of its ingredients 5. Participants who are using steroids or other drugs 6.Participants with active alcohol intake and/or drug abuse
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in EASI Score from baselineTimepoint: 56 DAYS | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement in CDSQ Score from baselineTimepoint: 56 DAYS | — |
Countries
India
Contacts
Public ContactDr K Mohammed Nasar
National Research Institute of Unani Medicine for Skin Disorders
Outcome results
None listed